Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin) (CONCERT)

Roche logo

Roche

Status

Completed

Conditions

Metastatic Colorectal Cancer

Treatments

Drug: Concomitant Bevacizumab
Other: Observational Chemotherapy

Study type

Observational

Funder types

Industry

Identifiers

NCT02612077
ML21696

Details and patient eligibility

About

This is a longitudinal, multicenter, prospective, pharmacoepidemiological study to evaluate progression free survival (PFS) in a real-life setting in participants with metastatic colorectal cancer (mCRC) starting chemotherapy combined with bevacizumab.

Enrollment

765 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Having colon or rectal metastatic adenocarcinoma, for which the physician decided during the inclusion visit to start a treatment with bevacizumab combined with a 1st, 2nd or 3rd line chemotherapy
  • Having received oral and written information about the survey and not objecting to having his/her data computerized

Exclusion criteria

  • Participating in a clinical trial assessing an anticancer treatment

Trial design

765 participants in 1 patient group

Observational Chemotherapy/Bevacizumab
Description:
Observed patients receiving chemotherapy with concomitant bevacizumab
Treatment:
Other: Observational Chemotherapy
Drug: Concomitant Bevacizumab

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
Ā© Copyright 2024 Veeva Systems